lung cancer

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen claims FDA okay for would-be Tagrisso rival Rybrevan...

Johnson & Johnson's Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant as a treatment for EGFR-mutated non-small cell lung cancer (NSCLC).

News

FDA review of Lilly/Innovent's sintilimab paves way for cut-...

The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected to compete on price with rivals such as Merck & Co’s Keytruda.

News

BMS agrees deal worth up to $1.56bn for Agenus' TIGIT cancer...

Bristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to a cancer antibody still in the labs of US biotech Agenus, which blocks the

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

Patients in England get fast access to AZ's Tagrisso in earl...

The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early stage lung cancer, with NICE allowing fast access to patients on E

News

Roche's Tecentriq gets fourth European NSCLC indication

Roche’s cancer immunotherapy Tecentriq has been granted a new use by European regulators, for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC)

Events